Skip to main content
editorial
. 2022 Jun;14(6):1766–1771. doi: 10.21037/jtd-22-432

Table 2. Mechanisms of acquired osimertinib resistance (18-21).

On target
   EGFR mutations: C797S, L718Q, G724S, C79X, L792X, G769X, S768I, G724S, G796S, V834L exon 20 insertion
   EGFR amplification
Off target
   MET amplification
   HER2 mutation/amplification
   PIK3CA mutation/amplification
   KRAS mutation/amplification
   PTEN mutation
   Cell cycle gene alterations: CCND1, CCND2, CDKN2A, CDK6, CCNE1
   Small cell transformation
   Squamous translocation

EGFR, epidermal growth factor receptor.